Myelin basic protein content of aggregating rat brain cell cultures treated with cytokines and/or demyelinating antibody: effects of macrophage enrichment.
The demyelinative potential of the cytokines interleukin-1 alpha (IL-1 alpha), interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha) has been investigated in myelinating aggregate brain cell cultures. Treatment of myelinated cultures with these cytokines resulted in a reduction in myelin basic protein (MBP) content. This effect was additively increased by anti-myelin/oligodendrocyte glycoprotein (alpha-MOG) in the presence of complement. Qualitative immunocytochemistry demonstrated that peritoneal macrophages, added to the fetal telencephalon cell suspensions at the start of the culture period, successfully integrated into aggregate cultures. Supplementing the macrophage component of the cultures in this fashion resulted in increased accumulation of MBP. The effect of IFN-gamma on MBP content of cultures was not affected by the presence of macrophages in increased numbers.
Loughlin
A J
AJ
Multiple Sclerosis Laboratory, Institute of Neurology, London, United Kingdom.
Honegger
P
P
Woodroofe
M N
MN
Comte
V
V
Matthieu
J M
JM
Cuzner
M L
ML
D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases / Q000032:analysis; D000818:Animals; D000911:Antibodies, Monoclonal / Q000633:toxicity*; D001253:Astrocytes / Q000187:drug effects; D015415:Biomarkers; D001790:Blood Physiological Phenomena; D002449:Cell Aggregation; D002478:Cells, Cultured; D003165:Complement System Proteins / Q000494:pharmacology; D016895:Culture Media, Serum-Free; D016207:Cytokines / Q000633:toxicity*; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000503:physiopathology; D005974:Glutamate-Ammonia Ligase / Q000032:analysis; D006168:Guinea Pigs / Q000097:blood; D007371:Interferon-gamma / Q000633:toxicity; D007375:Interleukin-1 / Q000633:toxicity; D017737:Macrophages, Peritoneal / Q000502:physiology*; D008562:Membrane Glycoproteins / Q000276:immunology*; D051379:Mice; D004676:Myelin Basic Protein / Q000378:metabolism*; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein; D009419:Nerve Tissue Proteins / Q000032:analysis / Q000276:immunology*; D009836:Oligodendroglia / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins; D013687:Telencephalon / Q000166:cytology* / Q000187:drug effects / Q000196:embryology; D014409:Tumor Necrosis Factor-alpha / Q000633:toxicity
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D016895:Culture Media, Serum-Free; D016207:Cytokines; D007375:Interleukin-1; D008562:Membrane Glycoproteins; C571327:Mog protein, mouse; C571328:Mog protein, rat; D004676:Myelin Basic Protein; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein; D009419:Nerve Tissue Proteins; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D003165:Complement System Proteins; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases; D005974:Glutamate-Ammonia Ligase